DK0646132T3 - Aminosukkere, glycoproteiner, fremgangsmåde til fremstilling deraf, lægemidler med indhold deraf samt anvendelse deraf - Google Patents

Aminosukkere, glycoproteiner, fremgangsmåde til fremstilling deraf, lægemidler med indhold deraf samt anvendelse deraf

Info

Publication number
DK0646132T3
DK0646132T3 DK94913578T DK94913578T DK0646132T3 DK 0646132 T3 DK0646132 T3 DK 0646132T3 DK 94913578 T DK94913578 T DK 94913578T DK 94913578 T DK94913578 T DK 94913578T DK 0646132 T3 DK0646132 T3 DK 0646132T3
Authority
DK
Denmark
Prior art keywords
immune system
glycoproteins
amino sugars
processes
preparation
Prior art date
Application number
DK94913578T
Other languages
English (en)
Inventor
Werner Reutter
Cora Schueler
Oliver Keppler
Michael Pawlika
Holger Kayser
Original Assignee
Werner Reutter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werner Reutter filed Critical Werner Reutter
Application granted granted Critical
Publication of DK0646132T3 publication Critical patent/DK0646132T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK94913578T 1993-04-12 1994-04-12 Aminosukkere, glycoproteiner, fremgangsmåde til fremstilling deraf, lægemidler med indhold deraf samt anvendelse deraf DK0646132T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4311580A DE4311580C1 (de) 1993-04-12 1993-04-12 Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
PCT/EP1994/001126 WO1994024167A1 (de) 1993-04-12 1994-04-12 Aminozucker, glycoproteine, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung

Publications (1)

Publication Number Publication Date
DK0646132T3 true DK0646132T3 (da) 2000-03-13

Family

ID=6485046

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94913578T DK0646132T3 (da) 1993-04-12 1994-04-12 Aminosukkere, glycoproteiner, fremgangsmåde til fremstilling deraf, lægemidler med indhold deraf samt anvendelse deraf

Country Status (8)

Country Link
EP (1) EP0646132B1 (da)
JP (1) JPH08501803A (da)
AT (1) ATE183204T1 (da)
AU (1) AU6567494A (da)
CA (1) CA2137833A1 (da)
DE (1) DE4311580C1 (da)
DK (1) DK0646132T3 (da)
WO (1) WO1994024167A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09183789A (ja) * 1995-10-31 1997-07-15 Sanwa Kagaku Kenkyusho Co Ltd 新規な硫酸化及び燐酸化糖誘導体、その製法及び用途
AUPP589398A0 (en) 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
DE10045047A1 (de) 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
AU2002336981A1 (en) * 2001-08-17 2003-03-03 Charite Glycoconjugates of sialic acid derivates, methods for their production and use thereof
WO2004011026A1 (en) * 2002-07-26 2004-02-05 The Walter And Eliza Hall Institute Of Medical Research Immunogenic compositions and diagnostic and therapeutic uses thereof
CA2890962A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines

Also Published As

Publication number Publication date
EP0646132B1 (de) 1999-08-11
DE4311580C1 (de) 1994-08-18
CA2137833A1 (en) 1994-10-27
EP0646132A1 (de) 1995-04-05
WO1994024167A1 (de) 1994-10-27
ATE183204T1 (de) 1999-08-15
JPH08501803A (ja) 1996-02-27
AU6567494A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
Djerassi et al. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer
PT82457A (en) Process for the preparation of pharmaceutical compound with base in phosphonil-methoxy-alkyl-adenines with antiviral activity
AU6642390A (en) Methods and compositions for promoting immunopotentiation
DE3684732D1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
BRPI0507822A (pt) método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
SE9201413L (sv) Beredning och sätt för aferesframställning av trombocytkoncentrat med väsentligt förlängd hållbarhet
STRINGFELLOW et al. Interferon induction by 5-halo-6-phenyl pyrimidinones
EP0308197A3 (en) Method for stimulating the immune system
DK0646132T3 (da) Aminosukkere, glycoproteiner, fremgangsmåde til fremstilling deraf, lægemidler med indhold deraf samt anvendelse deraf
DE3650505T2 (de) AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung.
Farnsworth Acute and subacute glomerulonephritis modified by adrenocorticotropin.
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
Alan et al. Interferon α/β selectively antagonises down-regulation of mannosyl-fucosyl receptors on activated macrophages by interferon γ
Alalawi et al. Combined effects of bleomycin and X-rays on DNA synthesis in asynchronous Ehrlich ascites cells in suspension
US4874608A (en) Therapeutic method for treating malignancies
ES550932A0 (es) Procedimiento para la determinacion cinetica de la actividad del sistema de complemento de sangre de ser humano o de animal mamifero.
Naoum et al. Treatment of herpes zoster with interferon alpha-2A.
SU1507380A1 (ru) Способ лечени расстройств слуха
SU1600502A1 (ru) Способ приготовления эритроцитарного диагностикума для индикации лекарственной аллергии к антибиотикам
AU2366388A (en) A method for the preparation of a pharmaceutical curative for the veterinary and humane medicine, with antiviral and antitumoral effect
RU98108179A (ru) Способ лечения инфекционного мононуклеоза у детей
GR1002969B (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε αιωρημα εμβρυικων κυτταρων με δραση ανοσοποιητικης υποκαταστασης και μεθοδος θεραπειας του συνδρομου της επικτητης μολυνσης ανοσοποιητικης ανεπαρκειας (hiv) με τη χρηση αυτου του παρασκευασματος.